EPIX vs. FHTX, TNGX, VYGR, NMRA, IMMP, CADL, KOD, NGNE, RZLT, and ENGN
Should you be buying ESSA Pharma stock or one of its competitors? The main competitors of ESSA Pharma include Foghorn Therapeutics (FHTX), Tango Therapeutics (TNGX), Voyager Therapeutics (VYGR), Neumora Therapeutics (NMRA), Immutep (IMMP), Candel Therapeutics (CADL), Kodiak Sciences (KOD), Neurogene (NGNE), Rezolute (RZLT), and enGene (ENGN). These companies are all part of the "pharmaceutical products" industry.
ESSA Pharma vs.
ESSA Pharma (NASDAQ:EPIX) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership, risk and community ranking.
ESSA Pharma presently has a consensus target price of $9.50, indicating a potential upside of 452.33%. Foghorn Therapeutics has a consensus target price of $13.17, indicating a potential upside of 151.75%. Given ESSA Pharma's higher possible upside, equities analysts plainly believe ESSA Pharma is more favorable than Foghorn Therapeutics.
ESSA Pharma has higher earnings, but lower revenue than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, ESSA Pharma had 17 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 18 mentions for ESSA Pharma and 1 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 1.94 beat ESSA Pharma's score of 0.08 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.
ESSA Pharma received 309 more outperform votes than Foghorn Therapeutics when rated by MarketBeat users. Likewise, 75.87% of users gave ESSA Pharma an outperform vote while only 63.49% of users gave Foghorn Therapeutics an outperform vote.
75.1% of ESSA Pharma shares are owned by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are owned by institutional investors. 15.5% of ESSA Pharma shares are owned by insiders. Comparatively, 9.1% of Foghorn Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
ESSA Pharma has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.18, suggesting that its share price is 218% more volatile than the S&P 500.
ESSA Pharma has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -357.53%. Foghorn Therapeutics' return on equity of 0.00% beat ESSA Pharma's return on equity.
Summary
ESSA Pharma beats Foghorn Therapeutics on 11 of the 18 factors compared between the two stocks.
Get ESSA Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ESSA Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:EPIX) was last updated on 2/22/2025 by MarketBeat.com Staff
